Tag: lundbeck

September 22, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Lexicon Soars

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
September 16, 2019

Lundbeck to Buy Alder BioPharma in US$2 Billion Deal

Lundbeck will add Alder BioPharma's potential blockbuster migraine treatment, eptinezumab, to its pipeline ahead of patent expirations.
November 2, 2016

Lundbeck Raises 2016 Financial Guidance Based on Improved Sales and Profitability

Lundbeck today announces financial results and raises financial guidance for 2016.
June 13, 2016

Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective

TURKU, Finland–(BUSINESS WIRE)–Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie” or the “Company”) announces that the voluntary delisting of its American...
May 18, 2016

Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market

TURKU, Finland–(BUSINESS WIRE)–Biotie Therapies Corp. (“Biotie”) today announces that its Board of Directors has resolved to voluntarily delist its American...
April 22, 2016

FDA Accepts Lundbeck Resubmission of New Drug Application for Carnexiv™ (carbamazepine)

DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of...
April 20, 2016

ACORDA THERAPEUTICS TO COMMENCE A COMPULSORY REDEMPTION PROCEEDING IN RESPECT OF THE REMAINING BIOTIE THERAPIES CORP. SHARES

BIOTIE THERAPIES CORP.         STOCK  EXCHANGE  RELEASE    20 April 2016, at 4.50 p.m. (EET) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY...